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ABSTRACT
EFFICACY OF ZINC SUPPLEMENTATION
IN REDUCING THE INCIDENCE OF RECURRENT VAGINITIS
By
Bonnie R. Bartz
The purpose of this study was to evaluate the efficacy of zinc supplementation in
reducing the incidence of recurrent bacterial vaginosis (BY) and vulvovaginal candidiasis
(W C ). Forty-one subjects were selected from researcher’s patients based on at least two
episodes of vaginitis in a six-month period. A control group (placebo) and an experimental
group (30 mg zinc gluconate) were randomly formed from this selection.
Evaluation of vaginitis status was accomplished through wet mounts, pH test, and
KOH whiff tests at the initial, 3, and 6-month intervals. Subjects sought treatment for
vaginitis when symptomatic.
A t-test analysis showed no statistically significant difference in the overall incidence
of vaginitis between the control group and the experimental group (t = 1.45, df = 22, p =
0.16). The incidence of W C in the zinc group decreased from 19 to 5 post treatment (t =
2.23, p = 0.021).
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CHAPTER I
INTRODUCTION

Vaginitis accounts for more visits to the obstetrics and gynecology office than any
other female condition (Mead & Eschenbach, 1998). An estimated 5 - 10 million office
visits per year are made due to vaginitis (Faro, 1994). In 1991, U.S. women spent over
$ ICO million dollars on over the counter yeast treatments (Foxman, 1997).
Bacterial vaginosis (BY) is the most common vaginal infection. It is estimated that
50 - 64% of sexually active women have at least one episode of BY (Selleck, 1997).
Vulvovaginal candidiasis (yeast infections or VYC) are the second most common vaginal
infection. An estimated 75% of women will have a VYC infection at least once in their lives
(Nyiijesy, 1997). Approximately 5% of women with one episode of YYC will suffer
difficult or recurrent infection. Recurrent infection is commonly defined as four
mycologically proven symptomatic episodes of YYC in 12 months (Nyiijesy, 1997).
Recent research links BY to serious gynecological, obstetrical, and general medical
risks, including upper reproductive tract and postoperative infections, adverse pregnancy
outcomes, preterm labor, cervical dysplasia, mucosal barrier disruption, and increased
transmission of Human Immunodeficiency Virus (HTY), Human Papilloma Virus (HPY),
and Herpes Simplex Virus (HSY) (Secor, 1997). Little research has been done in finding
nursing interventions that may help decrease the recurrence rate of vaginitis in women who
are prone to recurrent infections.
Health care professionals have long known that zinc is needed by the human body
for optimal well-being, especially for maintaining a healthy immune system. The use of
topical zinc has been recommended in the treatment of genital herpes (Northrup, 1994).

High levels of serum zinc have been observed as a protective factor against HPV in women
(Liu, Soong, Alvarez, & Butterworth, 1995) and HTV (Secor, 1997). Zinc has also been
found to have an antitrichomonal activity (Houang, Ahmet, & Lawrence, 1996). Zinc
deficiency has been demonstrated to reduce the immunity of inbred strains of mice to
infection with C. albicans (yeast), while zinc excess or sufficiency was a protective factor
against Candida (Edman, Sobel, & Taylor, 1986).
This author identified no studies on the use of supplemental zinc to help prevent
vaginal infections. “Research that describes the microfloral ecosystem of the vagina or
examines therapeutic or preventive modalities based upon écologie tenets is sparse”
(Overman, 1993, p. 146). “The scientific literature increasingly supports the impact of
lifestyle on health maintenance and disease prevention; yet, there are few scientific data to
support the role of nutrition, exercise, stress reduction, and general health maintenance in the
management of sexually transmitted diseases (STDs) and vaginitis” (Roe & Gudi, 1997, p.
275).
Many patients seek a natural remedy for health care ailments. “In a given year
about a third of all American adults use unconventional medical treatments. The most
frequent users are educated, upper income White Americans in the 25 to 49 year age range”
(Youngkin & Israel, 1996, p. 39). Because patients are seeking newer, unconventional
treatments for common health care concerns, nurses must embrace the study of safe,
complementary and alternative treatment methods. Therefore, the purpose of this study was
to determine if the use of supplemental zinc would decrease the incidence of vaginitis in
women prone to recurrent infection.

CHAPTER 2
CONCEPTUAL FRAMEWORK AND LITERATURE REVIEW

Conceptual Framework
Nursing Theory - Neuman's Systems Model
Basic theory. The Neuman’s Systems Model ( 1993) was the theoretical framework
for this thesis. The model can best be explained by using a diagram consisting of several
concentric circles (see Figure 1). The inner circle is the “basic structure” and represents
the individual, family, or a system. The basic structure has several common factors
including: normal temperature range, genetic structure, response pattern, organ strength or
weakness, and knowns or commonalties (a common range of normal characteristics and
responses).
The next in the series of circles are the “lines of resistance”. These lines represent
the body’s defenses that are involuntarily activated when a stressor invades the normal line
of defense. They attempt to stabilize the client to return to the normal line of defense
(Neuman, 1993).
The “normal line of defense” is the next outer circle. It represents the normal
wellness level, or what the client has become. It is a result of the client’s previous
interactions with environmental stressors, or more simply, her coping skills. It is the
standard from which deviances from wellness can be judged (Neuman, 1993).
The outermost concentric circle is the “flexible line of defense”. It represents a
protective buffer for the client’s normal state. It serves to prevent an invasion of stressors.

Basic structure
Basic factors common to
all organisms include:
e Normal temperature
range
e Genetic structure
e Response pattern
# Organ strength
e W eakness
# Ego structure
# Knowns or commonalities

'Sÿÿan

Basic
structure
Energy
resources

NOTE: Physiologic, psychologic, sociocultural,
developmental, and spiritual variables occur
and are considered simultaneously in each
client concentric circle.

Figure 1. Diagram of the Client System. From "The Neuman Systems Model," by
B. Neuman, 1989, p. 28. Copyright 1989 by Appleton & Lange. Used with permission of
the author.

This line can be thought of as accordion-like. The further away it is from the normal line of
defense, the stronger it is. This line varies easily and is affected by nutrition, exercise,
mental, physical, and spiritual health (Neuman, 1993). Definitions of Neuman’s paradigm
concepts are listed below. Application of each concept to the proposed study is clarified.
Concepts. Neuman defines her paradigm concepts as:
1. Person - a composite of five variables: Physiologic, psychologic, sociocultural,
developmental, and spiritual. Zinc supplementation is proposed to affect the physiologic
variable.
2. Environment - has internal and external components. This can be thought of as
the vaginal ecosystem.
3. Health - Varying degrees of harmony and balance between internal and external
environment through a process of interaction and adjustment. Zinc may affect the balance
of health by strengthening natural killer cell activity in the vagina.
4. Nursing - Primary goal is retention, attainment, or maintenance of client stability
(Fawcett, 1995). The goal for nursing could be the vagina’s ecological or physiological
stability.
Assumptions. Neuman outlined ten basic assumptions inherent in the Neuman
Systems Model (Fawcett, 1995). For the purpose of this paper, the following will be
defined:
1. Though each client is unique, each system is a composite of common known
factors or innate characteristics within a normal, given range of responses, contained within
a basic structure.
2. Many known environmental stressors exist. Each differs in its potential for
disturbing a client’s usual stability level, or normal line of defense. Particular client
variables (in this study the physiologic variable), can affect the degree to which a client is
protected by the flexible line of defense against a possible reaction to a stressor.

3. Each client, over time, has evolved a normal line of defense. This line varies for
each individual. Some people are more resistant than others.
4. When the cushioning accordion-like effect of the flexible line of defense is no
longer capable of protecting the client against an environmental stressor, the stressor breaks
through the normal line of defense. The interrelationships of variables - physiological,
psychological, sociocultural, developmental, and spiritual - determine the nature and degree
of the system reaction to the stressor.
5. The basic structure is a dynamic composite of the interrelationships of the five
variables. Wellness moves on a continuum of available energy to support the system in its
optimal state.
6. Implicit within each client system is a set of internal resistance factors known as
lines of resistance, which function to stabilize and return the client to the usual wellness level
(normal line of defense).
7. Primary prevention relates to general knowledge that is applied in client
intervention and reduction of risk factors associated with stressors to prevent possible
reaction. This would include client education for basic vaginal hygiene.
8. Secondary prevention relates to symptomatology following a reaction to
stressors, and treatment to reduce their noxious effects. This would include treatment of a
vaginal infection.
The Neuman’s System Model has a unique focus on the wellness of the client in
relation to environmental stress and reactions to stress (Fawcett, 1995). It allows easy
conceptualization of how optimal nutrition, including zinc supplementation, could strengthen
the body’s resistance to recurrent vaginal infections.
Vaginitis Theory
To conceptualize how zinc may affect the vagina’s resistance to inflection, the author
developed a diagram of the vagina and its ecosystem patterned after Neuman’s Model
( 1989) (see Figure 2). In the author’s diagram, Neuman’s basic structure represents the

vagina, which includes a number of basic factors including normal temperature range,
genetic structure, response pattern (to stressors), and organ strength or weakness (skin
integrity, general health of woman).

Vagina
Basic factors common to the vagina include:
• Normal temperature range
• Genetic structure
• Response pattern to stressors
• Organ strengtti and weakness
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Figure 2. Vaginal Ecosystem Based on Neuman's Systems Model

Neuman’s lines of resistance represent the vaginal ecosystem (vaginal microecology
system). The vaginal ecosystem contains many microorganisms that stabilize the vagina
and attempt to return the vagina to its normal state. Lactobacilli is the dominant organism
present in the normal vaginal ecosystem. These lactobacilli produce hydrogen peroxide
which keeps the vaginal pH acidic and prevents overgrowth of bacterial pathogens (Sobel,
Cook, & Redondo-Lopez, 1991). Lactobacillus acidophilus is thought to maintain
ecological control in the vagina by competing with other organisms for adherence to the
vaginal wall, producing protein inhibitors with antimicrobial properties and stimulating the
immune system (ReDondo-Lopez, Cook, & Sobel, 1990).
When the vaginal ecosystem is dismpted either by a change in the vaginal flora or a
change in the host tissue, vaginitis can occur (Overman, 1993). Changes in the normal flora
can be due to age, hormone status, excessive douching, pregnancy, influence of drugs
(especially antibiotics), intrauterine device use, frequent intercourse, new sex partner, or a
compromised immune status (Kent, 1995; Ament & Whalen, 1996; Star, 1995; Tobin,
1995). When the normal flora are altered, pathogenic bacteria flourish (Kent, 1995). T
cells also exist in the vaginal vault and are responsible for attacking foreign organisms. A
logical conclusion then is that maintaining a healthy vaginal ecosystem is an important
factor in preventing vaginal infections.
Changes in the vaginal ecosystem can also be due to stress. Stress results in large
amounts of both adrenal and glucocorticoids being released into the blood stream (Cataldo,
DeBruyne, & Whimey, 1995). “One of the most significant effects of stress-induced
secretion of glucocorticoids is seen in immunologic function. Excessive glucocorticoids
produce anti-inflammatory effects. Glucocorticoids also inhibit the release of histamine and
other kinnins, thus limiting the physiologic cascade of events involving the inflammatory
response. The result is anti-inflanmu^on and increased susceptibility to infection” (Sikes,
1992, p. 385).

The normal line of defense represents the normal state of the vagina. This is
affected by the general health and well being of the woman. For instance diabetes, AIDs,
autoimmune disorders, and a high-stress lifestyle can make a woman more prone to
recurrent vaginal Infections.
The flexible line of defense is a protective buffer and acts to prevent invasion of
stressors. The flexible lines of defense are the interrelationships of physiological,
psychological, sociocultural, developmental, and spiritual variables. These variables
determine how susceptible a woman will be to stressors and also affect the balance of the
vaginal ecosystem. Because this line is affected by nutrition (physiologic variable), zinc
supplementation may strengthen the flexible line of defense.
In summary, Neuman’s Model (1989) and the author’s vaginitis theory are
comprised of 4 components. For the purpose of this study, Neuman’s basic structure
represents the vagina. Neuman’s lines of resistance represent the vaginal microecology or
vaginal ecosystem. Neuman’s normal lines of defense are perceived as the normal state of
the vagina. Neuman’s flexible lines of defense remain unchanged as the interrelationship of
the five variables stated above.
Review of Literature
This section reviews several studies that have linked zinc deficiency to recurrent
vaginal infections. The studies have focused on candidiasis, trichomoniasis, and Human
Papillomavirus. The candidiasis study measured plasma and tissue concentrations of zinc,
while the trichomoniasis study focused on treatment with zinc douches. Several studies
have been done on the use of topical zinc in wound healing that suggest positive results.
Zinc oxide has long been used as an over the counter treatment for and prevention of diaper
rash, athlete’s foot, and sunburn. The researcher has not found any studies involving oral
zinc supplementation as a prevention modality for vaginitis.

Zinc
Zinc properties. The mineral, zinc, plays an important role in the formation of
protein in the body and thus assists in wound healing, blood formation, and general growth
and maintenance of all tissues. Zinc is a component in many enzymes and is, thusly
involved in most metabolic processes (USDA, 1990). Another property of zinc, which has
been hypothesized to play a role in normal physiological function, is zinc’s capacity to
stabilize membranes. This effect has been observed where zinc protects against various
inducers of hemolysis such as bacterial toxins (Walsh, Sandstead, Prasad, Newbeme, &
Fraker, 1994).
Delayed wound healing is a sign of moderate zinc deficiency. Recent studies show
that a mild or marginal deficiency of zinc in humans is characterized by decreased natural
killer cell activity and alterations in T cell subpopulations (Walsh et al.).
Zinc is a relatively safe mineral. Doses up to 6 times the Recommended Daily
Allowance (RDA) are considered nontoxic in the healthy individual (Walsh et al.). Taking
more than 100 mg a day of zinc for extended periods of time could result in problems such
as depressed immune function and imbalances of copper. The use of high doses of zinc for
longer than seven days at a time is not recommended (Herb Research Foundation, 1997).
The US RDA of zinc is 15 mg for males, 12 mg for females, and 15 mg for
pregnant women (Walsh et al.). Studies show that many US adults get only 9.9 mg a day,
and typically women average only 8.1 mg per day (American Zinc Association, 1997).
The cost of oral zinc supplements averages $5.(X) for 100 capsules (30 to 50 mg) or
$ 1.50 per month, significantly less than the average $ 15 for over the counter W C
treatments. A rare side effect is mild gastric distress. Taking the capsule with food can
alleviate this.
Zinc toxicity. The average US citizen is at far greater risk of becoming zinc
deficient than experiencing adverse health effects as a result of exposure to high zinc levels.
Determining what effects excess zinc has on immune function is more problematic because
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exposure to such levels is rare, and available literature is limited (Walsh et al.). A 1984
study suggests evidence that excessive zinc intake is toxic to the immune system. In this
study, 11 adult males were given 3(X) mg of elemental zinc daily for 6 weeks. This level is
20 times the RDA. This study is considered to have several flaws. Because high levels of
zinc intake can cause copper deficiency, a major flaw in this study was the failure to assess
serum copper levels in the study subjects. Another flaw concerns the measures used to
assess immune status. Results of this study showed a depressed proliferative response of
lymphocytes, yet no change in the absolute number of lymphocytes and T and B cells. Also
noted was a reduction in the ability of phagocytic bacteria (Walsh et al.).
A second study involved giving elderly subjects 440 mg of zinc sulfate a day for one
month. This study found that high levels of zinc intake had no adverse immunological or
physiological effects on the elderly (Walsh et al.).
The major consequence of long-term ingestion of excessive zinc supplements is
induction of secondary copper deficiency caused by competition between these elements for
intestinal absorption. Levels of zinc supplements as low as 45 mg per day have negatively
influenced copper status (Severus, Oepen, & Stoll, 1996). Long term zinc supplementation
in excess of 150 mg per day has also been reported to result in low high density lipoprotein
(HDD levels, gastric erosion, and depressed immune function (King & Keen, 1999).
Chronic zinc toxicity is characterized by gastric problems, hypocupremia, and reduced HDL
cholesterol (The Herb Research Foundation, 1997).
“Acute, high level exposure to zinc compounds can produce respiratory and
gastrointestinal toxicity. However, these effects are largely self-limiting and require only
modest medical attention.” (Walsh et al., p. 34). Most exposures at these levels have been
through inhalation of smoke bombs or chronic exposure to fumes that are byproducts of
welding. Signs of acute zinc toxicity include: gastric distress, dizziness, and nausea.
Calcium and zinc absorption. Calcium supplementation at levels of 15(X) mg per
day has been shown to decrease zinc absorption (Tufts University Health & Nutrition
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Letter, 1997). In 1997, Wood and Zheng investigated the effects of calcium
supplementation on zinc absorption and balance in 18 relatively healthy, postmenopausal
women aged 59-86 years. All subjects received a standardized diet of typical foods
supplying 17.6 mg of zinc, and 890 mg of calcium during a 36 day period. The zinc
balance study was divided into three, 12 day experimental periods. In two of the three
cycles an additional 468 mg of calcium was added to the participant’s diet. Net zinc
absorption and zinc balance were significantly reduced by approximately 2 mg per day
during both high calcium treatment periods (p < 0.05). Measurements were obtained from
urine samples and fecal specimens. The researchers stated that “The mechanism through
which high calcium diets influence net zinc absorption is poorly understood’’ (Wood &
Zheng, 1997, p. 1808).
Zinc and the common cold. Several studies have been done using oral zinc
gluconate lozenges (23 mg) to reduce the length and severity of common cold symptoms.
At least eight studies have been performed. Of these studies, four found that zinc
supplementation was beneficial, and four found that it was not (Jackson, Peterson, & Lesho
1997). The average dose of zinc gluconate supplementation in those studies was 23 mg
every 2 hours while awake for 7 - 1 0 days. That is an average of 184 mg daily.
Immunopathologv of zinc deficiencv. Studies on dietary zinc deficiency on the
immune function of rodents represents the best developed paradigm regarding the effects of
a nutritional deficiency on host defense systems. These studies indicate that zinc is
essential to maintaining the integrity of the immune system (Walsh et al.). Information
gathered to date indicates that a 30 day period of suboptimal intake of zinc in the young
adult mouse, which produced a 20 to 25% weight loss, reduced the thymus to a quarter
normal size and depleted the lymphocytes and macrophages in the spleen 50 - 75% (Walsh
et al.). The thymus gland has a profound influence on overall immune system response in
individual cells and blood and lymph (Scheer, 1998). Antibody mediated responses to both
T-cell dependent and T-cell independent antigens were reduced 50 to 70%. Delayed-type
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hypersensitivity skin reactions, and the function of natural killer cells were also significantly
reduced in zinc deficient mice (Walsh et al.). Antibody mediated responses are key to
immune defense against a variety of pathogens, so such reductions explain the increased
incidence of infection observed in zinc-deficient subjects (Walsh et al.).
Zinc deficiency can lead to many complications, including reduced immune function
(American Zinc Association Newsletter, 1997). “Zinc deficiency is associated with
depression of a number of cellular immune functions, including delayed-type hyper
sensitivity reactions, T-helper cell activity, development of cytotoxic T cells, natural killer cell
activity, and mitogen-induced T-lymphocyte proliferation” (Edman, Sobel, & Taylor, 1986,
p. 1084).
Edman et al. (1986) state that zinc deficiency has been demonstrated to reduce the
immunity of inbred strains of mice to infection with C. albicans, while zinc excess or
sufficiency was a protective factor against Candida. In theory then, correcting a zinc
deficiency would help maintain a normal colonization of lactobacilli in the vagina.
Zinc deficiencies result in decreased antibodies and lymphocytes, leading to
impaired body fluids and cell-mediated immunity, as well as an increased susceptibility to a
variety of infections (Scheer, 1998). Deficient zinc intake can profoundly depress both T
and B cell function. Depression of B and T cell formation is manifested as a progressive
increase in infections with opportunistic micro-organisms especially Candida albicans and
other fungi (Walsh et al.). Zinc is required as a cofactor for at least 70 different enzymes,
some of which are found in lymphocytes and are necessary for their function. Several
immunologic factors have been proposed to be associated with recurrent W C . Women
with recurrent W C have been found to have reduced antigen-specific-T-lymphocyte
reactivity (Nyiqesy, 1997).
Vaginitis
The pathophysiology of vaginal infections, both Candida (yeast) and bacterial, has
long been recognized as the disruption in the normal vaginal flora. The vaginal environment
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is a dynamic and a delicate ecosystem (Mardh, 1991). Normal vaginal pH is 3.8 - 4.2.
Normal vaginal flora consists of yeast, bacteria, and hydrogen-peroxide producing
lactobacilli. Lactobacilli, as stated earlier, are thought to maintain écologie control of the
vaginal ecosystem.
Bacterial vaginosis. BV is a major disruption in vaginal flora characterized by a
massive overgrowth of vaginal anaerobes, and the disappearance of Lactobacillus species,
especially those that produce hydrogen peroxide (Sobel, 1997). The relative lack of
normally occurring lactobacilli alters the ecosystem of the vagina (or the lines of resistance),
allowing anaerobes to predominate and producing metabolic by-products that raise the pH
level of the vagina. Research to date has not clarified the cause of the microecologic shift
resulting in BV (Overman, 1993). Amines, the end products of anaerobic metabolism,
produce a fishy smelling discharge that is the hallmark of BV (Star, 1995).
Vulvovaginal candidiasis. Yeast infection or vulvovaginal candidiasis (W C ) is an
upset in the homeostatic balance (normal line of defense) in the vagina that leads to an
overgrowth of the fungus yeast {Candida). Three main types of Candida affect the vaginal
tract: Candida albicans, Candida tropicalis, and Candida glabrata. Candida albicans is the
most common organism found. Over the counter yeast treatments kill only Candida
albicans, not the lesser found Candida organisms. The yeast organism gains access to the

vaginal mucosa primarily from the perianal area (Youngkin & Davis, 1994). The warm,
moist environment of the vulva and vagina, in combination with its close proximity to the
rectum, make it a favorable reservoir for colonization of the yeast fungus (Secor, 1997).
Candida albicans is found in the normal (asymptomatic) vaginal flora of premenopausal

non-pregnant women with a 11% prevalence rate (Secor). The hallmark symptom of W C
is vulvar pruritis (Foxman, 1997).
Zinc and vaginitis. Several studies have been done using zinc treatments for the
diagnosis of W C , trichomoniasis, or HPV. The author did not find any studies relevant to
zinc and BV.
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The first study reviewed evaluated the effects of potential risk factors such as HPV
16 and nutritional status on the course of cervical dysplasia. Liu, Soong. Alvarez, &
Butterworth (1995) found that women who were HPV 16 positive and had high levels of
plasma zinc were less likely to develop cervical dysplasia than those without high levels of
plasma zinc w ere. The study involved 206 women in Birmingham, Alabama. With the use
of data of four repeat evaluations of dysplasia at an interval of 2 months, specific
relationships between HPV-16 infection, plasma retinol and zinc levels, and dysplasia
progression were evaluated through longitudinal data analysis of generalized estimating
equations.
Andrews, Mylvaganam, and Yule, physicians from Norway and the United
Kingdom, undertook a study in 1994 involving resistant strains of Trichomonas vaginalis,
Tritrichomonas foetus, and Giardia intestinaiis. The activity of bacitracin with and without
the addition of zinc on the resistant strains was studied using isolates in aerobic and
anaerobic conditions on culture plates. Minimum Lethal Concentrations of bacitracin alone
against Trichomonas vaginalis were 1500 - 2500 iu/mL. By adding zinc to the bacitracin
the Minimum Lethal Concentrations needed to destroy T. vaginalis dropped to 250 - 400
iu/mL. The primary action of bacitracin zinc is thought to be directed at the bacterial cell
wall. The activity of bacitracin against Trichomonas was enhanced 5 -1 0 times with the
addition of zinc. This was true in both aerobic and anaerobic culture conditions and was
equally effective against isolates that were sensitive or insensitive to metronidiazole
(Andrews, Mylvaganam, & Yule, 1994).
The next study reviewed involved four patients with a 4 month to 4 year history of
culture-positive symptomatic trichomoniasis who had received a variety of therapies before
referral. The patients selected had documented evidence of recurrent symptomatic
trichomoniasis unresponsive to repeated courses of conventional therapy (metronidiazole).
Another criteria for inclusion in the study was evidence that the chronic recurrence was not
due to reinfection fiom an infected partner. The patients were instructed to douche with 25
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mL of zinc sulfate solution in 250 mL of distilled water. After douching, they inserted a
500 mg metronidiazole suppository vaginally. This therapy was given twice a day for the
first week, and then gradually tapered off over 5 months. At a review 2 to 5 months after
therapy, all patients remained asymptomatic and culture negative (Houang, Ahmet, &
Lawrence, 1997). The exact role of zinc sulfate douching is not known, but the combination
of zinc and metronidiazole therapy achieved a cure in these patients at a dosage that had
failed before, when metronidiazole was used alone (Houang, et al., 1997).
Another case study involved a woman with trichomoniasis who failed to respond to
high dose metronidiazole, over a 4 month time frame. At completion of this therapy she was
still found to be culture positive. She was admitted for intravenous (IV) metronidiazole
therapy, 500 mg three times a day for 5 days. Within one week of IV therapy, urethral and
vaginal cultures were positive for trichomoniasis. At this stage, plasma and urinary zinc
levels were measured. Her plasma zinc level was 9 (normal 12 - 20), and urinary zinc level
was 3 (normal 4 -12). She was prescribed zinc sulfate, 220 mg orally twice a day for 3
weeks. Her plasma zinc level rose to 12. After 15 months of recurrent infection, this patient
was culture negative for four months after treating her low plasma zinc level (Willmott, Say,
Downey, & Hookham, 1983).
A specific study on zinc and candidiasis took place in 1985. Drs. Edman, Sobel,
and Taylor evaluated the relationship between zinc status and recurrent vaginal candidiasis.
Twenty-nine subjects with at least 3 documented episodes of acute Candida vaginitis in the
previous 12 month period comprised the experimental group. The control group consisted
of 20 women who had never been diagnosed with vaginal candidiasis. The two groups were
matched for age, race, and parity. None of the subjects were pregnant, postmenopausal, or
had any chronic health conditions. Seven subjects with recurrent vaginitis (24.1%) were
taking zinc-containing supplements, while five control subjects (25%) were taking zinccontaining supplements. Dietary zinc intake was assessed based on 3 day food
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consumption records. The results suggested that dietary zinc intake between the two groups
was not statistically significantly different (p = 0.190).
Plasma zinc measurements were then obtained from both groups. The mean plasma
zinc concentration in the recurrent vaginal candidiasis group was 87 pg/dl in zincsupplemented women and 79 p,g/dl in non-zinc-supplemented women. In the control group,
mean plasma zinc levels were 95 pg/dl in the zinc-supplemented women, and 91 pg/dl in the
non-zinc-supplemented women. The mean plasma zinc concentration was significantly
lower in women with recurrent vaginitis not receiving zinc supplements (79 pg/dl) when
compared with control nonsupplemented women (91 pg/dl.) (p = 0.015). Comparison of
the women in both groups who were receiving zinc supplements showed the plasma
concentration was lower in women with recurrent infection (87pg/dl), than in the control
group (95 pg/dl), but this was not statistically significant (p = 0.52) (Edman et al., 1986).
The results of this study suggest that women in the group not receiving zinc with
recurrent vaginal candidiasis had significantly lower mean plasma zinc levels than women
who had never had an episode of Candida vaginitis. Limitations of this study include the
fact that the zinc supplements were not standardized. There is no indication of how many
milligrams of zinc the women were taking or whether it was the same type of zinc (i.e., zinc
gluconate, zinc acetate, etc.) (Edman et al.).
Edman et al. suggest that "additional studies are required to correlate zinc status in
women with recurrent vaginal candidiasis. Controlled longitudinal studies are necessary to
correlate the effects of zinc supplementation with immune status in susceptible women and
to evaluate the effects of zinc supplementation on the clinical recurrence rate of Candida
vaginal infection. In light of the available data correlating acquired zinc deficiency with
reduced T-lymphocyte function, a parameter known to be impaired in women with recurrent
vaginal candidiasis, zinc deficiency may be a contributing factor in some women with
recurrent vaginal candidiasis” (1986, p. 1085).
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Following publication of the previously reviewed study, Bohler, Meisinger, Klade
and Reinthaller ( 1994) undertook a study measuring zinc levels of serum and cervicovaginal
secretions in women with recurrent W C . Twenty-one women with at least three
documented episodes of W C within the previous 12 months, and 15 women without W C
as a control group were investigated.
Results showed no significant difference in the mean plasma zinc concentrations
between the recurrent W C group ( 109 ng/dl) and the control group (107 |ig/dl).
Measurements of cervicovaginal secretions showed 30.2 pg/dl of zinc in the recurrent W C
group, and 29.6 |ig/dl of zinc in the control group. This difference was not significant. (No
normal zinc values of cervicovaginal secretions have been established). While no
confirmation of zinc deficiency in women prone to recurrent W C was found, “controlled
studies should help to clarify whether zinc supplementation affects clinical cure rate of
W C " (p. 310).
This study is limited by that fact that dietary zinc intake was not assessed. Also, it is
not known whether any of the subjects were using zinc supplementation. It is also not
known whether zinc levels in cervicovaginal secretions are a valid measurement in regards to
this topic (Bohler et al.).
Summary and Implications for Study
The vaginal environment has an innate immune system (lines of resistance).
Changes in the immune system, which disturb the delicate balance of lactobacilli, can result
in vaginitis. Zinc is known to enhance the immune system. Conversely, zinc deficiency can
negatively impact the vaginal immune system. Correcting a zinc deficiency, by a safe, costeffective method may decrease the incidence of recurrent vaginitis.
The literature points to several instances in which the use of zinc enhanced treatment
of resistant vaginitis. Research suggests that zinc supplementation can help the body’s
immune system response to infection. There is little data or knowledge available to nurses,
physicians, and the general public about what preventive measures can be taken to reduce
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the incidence of recurrent vaginitis. Zinc supplementation alone has never been studied in
relation to prevention or treatment of recurrent vaginal infections. Nursing could certainly
benefit from this study if a positive correlation is shown. Although this was a small study, it
provides a starting point for a more comprehensive research study in the future.
Purpose/Hypothesis
Maintenance of a healthy vaginal microecology is vital in the prevention of vaginitis.
Because zinc deficiencies can lead to impaired immune functioning, correcting a presumed
zinc deficiency may help maintain a normal colonization of lactobacilli in the vagina, thereby
reducing the incidence of recurrent vaginitis. The purpose of this study was to evaluate the
effect of oral zinc supplementation on the recurrence of vaginitis (either W C or BV) in
women ages 18-45 that are prone to recurrent vaginitis.
The research hypothesis stated women, between the ages of 18 - 45 with recurrent
vaginitis who take 30 mg of oral zinc supplementation, will have fewer cases of vaginitis
than women who do not supplement during a six month time frame.

Definition of Terms
Recurrent vaginitis is defined as two or more episodes of clinician-identified
vaginitis in a 6 month time frame.
Oral zinc supplementation for this study is defined as 30 mg of zinc gluconate daily
in capsule form.
Presence of clinician diagnosed vaginitis was evaluated during pre-determined study
intervals and/or as a result of patient request. Evaluation included a vaginal pH, a
microscopic saline wet mount, and a potassium hydroxide (KOH) whiff test. Three types
of vaginitis were assessed: Candida, bacterial vaginosis, and mixed infections (W C and
BV).
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CHAPTERS
METHODS

Research Design
This was an experimental, double-blind study. One group of women, the control
group, was given an oral placebo to take on a daily basis. The other group, the study group,
was given a zinc supplement to be taken daily. Comparisons were made between the two
groups to determine if zinc supplementation reduced the incidence of recurrent vaginitis.
The independent variable in the study was zinc supplementation. The dependent variable
was the incidence of vaginitis. The research assistant used a coin toss method to determine
which group the first participant would enter. Thereafter participants were placed in
alternate groups.
Sample and Setting
Sample
Women were identified through visits over the last 12 months to the researcher’s
private practice. They were asked to voluntarily participate in the study. Selection criteria
limited participation to non-pregnant, sexually active females, between the ages of 18 - 45.
Participants had no history of diabetes, were not pregnant, were not on any daily
medications other than contraceptives, anti-depressants, non-steroidal anti-inflammatory
drugs, antacids, or anti-hypertensives (in people with normal kidney function), were pre
menopausal, and were not intrauterine device (lUD) users. lUD use is thought to affect
normal vaginal flora (Star, 1995). Criteria for exclusion included conditions known to
influence zinc status such as inflammatory diseases, recent myocardial infarction, recent
surgery, chronic debilitation or malabsorption states, chronic infections other than vaginitis.
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and corticosteroid use (Edman et al., 1986). Chronic health conditions may affect
absorption and retention of zinc in the body. Therefore, women with chronic health
conditions were excluded from the study.
Participants were consumers who had been seen in the researcher’s practice in the
past year and found to have had at least two episodes of clinician diagnosed bacterial
vaginosis or yeast infection, or mixed vaginitis in a previous 6 month time frame.
Setting
The study site was a private practice obstetrics and gynecology office in a rural
community in a Midwestern state. This was a free standing, one floor, handicap accessible
building. The facility includes six modem exam rooms, and a lab where microscopies were
performed.
Instruments
Instruments of measurement in this study were the wet mount, the potassium
hydroxide (KOH) whiff test, the pH nitrazine paper test to diagnose vaginitis, and the 24hour diet recall to estimate average daily zinc intake. The researcher also occasionally used
a laboratory culture if it was deemed necessary. “If a wet mount has a questionable result, a
laboratory culture can help confirm or deny the presence of vaginal pathogens’’ (Sobel et
al., 1998). Anyone unresponsive to treatment received a urogenital culture. “Fungal culture
results will corroborate microscopic findings and are more sensitive than microscopic
examination to detect yeast” (Nyirjesy, 1997, p. 19).
24-Hour Diet Recall
To estimate the subject’s dietary zinc intake, the standard 24-hour diet recall method
was used. The study participants were asked to identify how many servings of all foods
they consumed in the last 24 hours, providing this was a normal intake for them. None of
the participants reported that the previous 24 hour time period had been atypical. This recall
determined if the subject’s intake fell within the average range of zinc consumption (8.1 mg
daily). Dietary recall was documented on the subject’s second visit, and was administered
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by the researcher. Participants were asked to estimate the size of their servings and given
visual aids of a 2 cup measure, a I cup measure, and a one-half cup measiue. Their average
zinc consumption was then estimated using information obtained from Bowes & Church’s
food values of portions commonly used (Pennington. 1994).
Diagnosis of Vaginitis
Patient historv. The patient history for diagnosing vaginal infections included a
description of vaginal symptoms with duration, sexual activity, current medical conditions
and medications (including use of herbs, vitamins, and over the counter preparations),
contraceptive methods (including use of condoms, spermicides or treated condoms), history
of STDs or vaginitis, hygiene habits, recent change in detergents or soaps, recent episodes
of douching, a description of aggravating or alleviating factors, family history of diabetes,
social history, and a menstrual history (Plourd, 1997; Star, 1995).
Diagnosis of BV included an accurate and thorough patient history, bimanual pelvic
examination, pH test, wet mount, and KOH whiff test (Plourd, 1997; Association of
Professors in Gynecology and Obstetrics [APGO], 1996). Diagnosis of BV is made by the
presence of 3 of the following 4 objective findings: abnormal discharge, elevated pH, amine
odor, and the presence of clue cells by microscopy (Star, 1995). The wet mount/KOH slide
of a patient with BV will have an obvious lack of lactobacilli, clue cells, WBCs, and may
have high concentrations of anaerobic bacteria such as Bacteroides, Mobiluncus, and
Gardnerella vaginalis. How this imbalance of lactobacilli and anaerobic bacteria causes
BV is not yet known (Selleck, 1997). Although unreliable alone for diagnosis, subjective
symptoms of BV include a mild to moderate discharge with a fishy odor (particularly worse
after intercourse), and mild vulvar irritation or burning.
Diagnosis of W C included an accurate and thorough patient history, pelvic exam,
pH test, and wet mount with KOH. A vaginal culture is also helpful when patients report
symptoms of W C , but have a negative wet mount. W C does not raise vaginal pH.
Subjective symptoms of W C include vulvar itching and an increased white clumpy or
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flocculent discharge. The patient with W C may also complain of dyspareunia, burning
with urination, and soreness (Sobel, Faro, Force, Foxman, Ledger, Nyirjesy, Reed, &
Sununers, 1998).
Physical exam. Physical examination to diagnose vaginal infections included a
close inspection of the vulva, vaginal walls and cervix for the presence of lesions, discharge
or erythema. The specula was lubricated with a small amount of warm water only as KY
jelly can affect pH readings. The vaginal discharge was examined for color, consistency,
odor, whether it was coming from the cervix, and if it was adherent to the vaginal walls. BV
discharge Is usually thin, homogenous, white, gray, adherent, malodorous, flocculent, and
sometimes increased (APGO, 1996). Signs of BV include: elevated vaginal pH, mild to
moderate milky discharge, with a fishy or amine odor.
Objective signs of W C are vulvar edema and erythema. The vulva and vagina are
often red, inflamed, and excoriated due to scratching. The uterus, adnexal, and rectovaginal
exam are within normal limits (Star, 1995). A vaginal discharge is common, and tends to be
thick, clumpy and white (Youngkin & Davis, 1994). Wet mount will show normal flora,
blastospores, and 40% - 50% of patients will be positive for pseudohyphae on the saline
side. On the 10% KOH side, the positive pseudohyphae will increase to 60% - 90% of
patients. See discussion immediately following for description of preparing a wet
mount/KOH prep. There will also be a decreased lactobacilli population (Sobel, 1997).
WBCs are present in mixed infections, as well as both yeast hyphae and clue cells.
Wet mount/KOH prep. A wet mount involves examining vaginal discharge under
the microscope. The wet mount is considered to be the key diagnostic test for BV (Selleck,
1997). EYeparation of a wet mount involves preparing two slides: one with 2 drops of
normal saline, the other with 2 drops of a 10% - 20% solution of KOH (potassium
hydroxide). Two separate swabs of vaginal secretions from the vaginal walls are obtained
using a clean wooden spatula. Use of Dacron or cotton swabs was avoided because the
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fibers may sometimes be mistaken for yeast hyphae on microscopic examination (Selleck,
1997).
The first sample of vaginal secretions was applied on the saline slide using two or
three rotations of the spatula to ensure a dilute sample. The second sample of vaginal
secretions was applied to the KOH slide. Ten to fifteen rotations of the spatula in the KOH
was used to assure a fairly concentrated sample (APGO, 1996). A “whiff test” with the
KOH slide was performed immediately. The KOH-vaginal fluid mix was sniffed to assess
for a strong, amine odor. The presence of this odor occurs in abut 50% - 75% of all
patients with BV (APGO, 1996).
The slides were then examined within 5 minutes of preparation under both low
power (4x - lOx objective) and high power (> 40x objective) settings. At low power, the
saline slide was observed for the presence of white blood cells (indicative of Trichomonas),
mobile pear-shaped organisms with a tail (Trichomonas), yeast buds or pseudohyphae, and
lactobacilli (long, rod-shaped). The KOH sample was examine for clue cells and
pseudohyphae. A clue cell is a vaginal epithelial cell with clumps of bacteria adherent to the
edges. At least 20% of observed epithelial cells should be clue cells to be of diagnostic
significance for BV (Sobel, 1997). “A normal vaginal pH, and a negative whiff test
eliminate 95% of all cases of BV” (Sobel, Personal Communication, 1998). A normal
vaginal slide would contain only vaginal epithelial cells and lactobacilli.
Wet mount interpretation depends on the skill of the clinician. The researcher has
been preparing and interpreting wet mounts for several years. She has also had two training
sessions at Wayne State University in 1998 with Dr. Jack Sobel, an internationally known
expert in the field of vaginitis. The researcher was the only clinician interpreting the wet
mounts, thus consistency was maintained.
Nitrazine paper pH test. The pH test provides a quick indication of what type of
infection the patient may have. A pH greater than 4 3 can indicate BV. Candida (yeast)
infections usually result in a pH of less than 4.5 (Sobel, 1997). Douching, water, recent
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intercourse, lubricants, cervical mucous, semen, spermicides, condoms, menstraal secretions,
and amniotic fluid can all result in altered pH (Sobel). The subjects were asked to refrain
from intercourse for 24 hours before their exams. They were questioned about recent
intercourse prior to their exams and all subjects denied this. To obtain a pH specimen, the
posterior and lateral fomices of the vagina were swabbed and the specimen was placed on
the pH paper. The cervical os was avoided due to cervical mucous lowering the pH value.
Evaluation of the pH level was done by comparing the color of the pH test strip to the color
key on the test strip container (APGO, 1996).
Procedure
The researcher kept a record for the past 12 months of women who presented to her
with recurrent vaginitis (2 or more infections in a six month time frame). All women
presenting with complaints of a vaginal infection underwent a physical exam, patient history,
KOH whiff test, wet mount, and pH test. Based on the researcher’s diagnosis, they were
treated with an appropriate medication (see Appendix F for office protocol for treating
vaginitis).
The women in the practice who had been identified as having recurrent vaginitis
were contacted by telephone by the researcher or the research assistant. The women were
invited to participate in the study. A letter that explained the procedure in more detail was
sent to the women who stated they were interested in participating in the study. The women
were scheduled a 30 minute appointment with the researcher to review the consent form in
detail, answer any questions, receive their initial exam (which included a patient history,
physical exam, wet mount, pH test, and KOH whiff test), and receive their supplements or
placebos.
After selection and informed consent were obtained, subjects were randomly placed
in either the study group or the control group by the research assistant using a coin toss
method initially, and then placed in alternating groups.
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The zinc capsules were removed from their original packaging by the research
assistant and placed in plain bottles obtained from a pharmacy labeled “B”. The placebo
capsules were prepared by a local pharmacy and placed in plain bottles labeled “A”. The
placebos were gelatin capsules filled with com starch. The research assistant had exclusive
knowledge as to which bottles contained the zinc, and which bottles contained the placebos.
The researcher did not have access to any information that revealed which capsule was the
zinc and which was the placebo.
Each participant was designated an individual sheet in the researcher’s notebook to
carefully track all data (Appendix B). This data included: age, race, name, patient
identification number, whether they were taking capsule A or capsule B, diet recall and
average zinc intake, any medications, vitamins, or herbal supplements they may have been on
during the course of the study, number and type of vaginal infections, treatment used, 3 and
6 month count of capsules, results of initial, 3, and 6 month wet mounts, KOH whiff tests,
pH tests.
Participants were asked to present to the researcher, free of charge, once every 3
months for a wet mount, pH test, KOH whiff test, and physical exam. Appointments were
scheduled that were convenient for the participants. The participants were also asked to
present at any time they had symptoms of a vaginal infection. These instructions were given
to them in writing, and reviewed with them verbally by either the researcher or the research
assistant. Findings of the 3 wet mounts, pH tests, and KOH whiff tests allowed the
researcher to detect any vaginal infections that may have gone unnoticed by the subject. A
wet mount, pH test, KOH whiff test, and physical exam at the time of vaginal symptoms
established the diagnosis of a vaginal infection.
When subjects returned for their 3 month interval visits, they were asked to bring in
their bottles of capsules to help determine if they were taking the capsules as directed. The
research assistant manually emptied and counted the remaining capsules and documented
this in her notebook. The researcher did not observe this activity. If it appeared the
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participant was not taking the capsules regularly, she was counseled by the research
assistant. At 3 months an interim history was obtained by the researcher, as well as a diet
recall. Questions asked were directed at any health changes, change in sex paitners, major
life stressors (Job change, moves, divorce), or dietary changes. These data were entered in
the researcher’s notebook.
The final 6 month visit included a physical exam, wet mount, pH test, KOH whiff
test, and another interim history. Any change in the subject’s situation was again noted in
the researcher’s notebook. If physical exam or patient history revealed signs or symptoms
of a STD, appropriate follow up would have been obtained. The researcher found no
subjects at risk for STD's by history or physical exam. No changes were implemented in
the procedural process during the study.
In order to minimize effects on absorption from other nutrients or supplements,
participants were instructed to take either the zinc 30 mg capsule or placebo at bedtime with
a food from an approved food list (see Appendix C). Foods containing calcium or iron
have the greatest effect on altering zinc absorption. Therefore, women were asked to take
their vitamin, mineral, or herbal supplements in the morning. At bedtime, or at least two
hours after meal consumption, they were instructed to take their zinc supplement or placebo
with either a glass of water alone, or with foods that do not contain significant amounts of
calcium or iron.
Vaginal infections can be a secondary effect of taking antibiotics. All study
participants were, therefore, asked to report any antibiotic therapy they used during the
course of the study. This was recorded in the researcher’s notebook. If a subject was
found to have a vaginal infection during the study, she was offered a standard treatment (see
Appendix F) and remained in the study. Both study groups were treated the same.
Human Subjects Protection
This study required that half the participants take 30 mg of zinc orally per day.
There are no known risks involved in using zinc supplementation at this level (Walsh et al..
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1994). The dosage of 30 mg was chosen because it is well tolerated, there is no danger of
toxicity, and it is readily available. This is well below the 300 mg dose where immuno
suppression is suspected (Walsh et al.). Women were told that if they were in the placebo
group, they were taking a gelatin capsule filled with com starch.
Subjects were assured of confidentiality and anonymity when they signed their
consent form (see Appendix A). They were assured that participating in the study would
not interfere with health care provided through the researcher’s office. They were advised
of any risks (zinc can cause nausea in some subjects). The list of participant’s names was
later destroyed for confidentiality.
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CHAPTER 4
RESULTS/DATA ANALYSIS

Data Analysis
Maintaining a healthy vaginal microecology is an important factor in preventing
vaginitis. Because zinc deficiencies can lead to impaired immune functioning, correcting a
presumed zinc deficiency may help maintain a normal colonization of lactobacilli in the
vagina, thereby reducing the incidence of recurrent vaginitis. The purpose of this
experimental double-blind placebo study was to evaluate the effect of oral zinc
supplementation on the incidence of vaginitis (either W C or BV) in women ages 18-45
that are prone to recurrent vaginitis. The statistical software program used was Minitab®.
The level of significance was set at p = .05.
Characteristics of Subjects
Fifty-six women were initially identified as meeting the inclusion criteria for the
study. These women were contacted by phone and asked to voluntarily participate. Fortyone women agreed to participate in the study. All women were Caucasian and between the
ages of 18 - 45. All of them lived within a 40 mile radius of the researcher’s office. At
each visit subjects were asked about specific stressors in their life, i.e.; job change, divorce,
separation, or death in the family. None of the participants stated they experienced any of
these stressors during the study.
Medications used by participants during the study included anti-depressants, oral
contraceptives, Depo-Provera contraception, pain relievers, antacids, and antibiotics. Herb
use among the participants was infrequent, however some participants reported using St.
John’s Wort, flsh oil, cranberry extract, echinacea, and acidophilus. Only one participant in
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the placebo group reported use of acidophilus. None of the participants had experienced a
recent birth or termination of pregnancy. None reported a change in sex partner or any
significant changes in their diet, health status, or weight. The participant’s occupations were
varied (e.g. accountants, waitresses, homemakers, teachers, bartenders, and clerical workers).
Participants who withdrew. Fifteen participants withdrew from the study after the
initial visit, leaving a total of 26 participants. The women who withdrew were of similar age
to the remaining subjects: m = 28.88 years in the placebo group (n = 8), and m = 29.83
years in the zinc group (n = 7). The number of previous vaginal infections was similar as
was as their vitamin and contraceptive use. Table 1 compares several characteristics of
participants who stayed in the study with those who withdrew.

Table 1
Comparison of Participants with Those who Withdrew (N = 4H

Age range

Study Participants
N = 26

Subjects who Withdrew
N = 15

18-44 years

17 - 39 years

Contraceptive users

12(m = 2.2)

5 (m = 3)

Vitamin/Calcium users

10 (m = 2.6)

5(m = 3)

Prior vaginal infections

m = 2.9

m = 2.6

Potential Intervening Variables
This section will examine the characteristics of the 26 women who remained in the
study. In order to determine if there were any potential intervening variables that were
different between the placebo group and the zinc group, nine characteristics of the
participants were examined. Table 2 summarizes these characteristics. It appeared there
were no differences in the participant’s age, zinc intake, prior vaginal infection rate.
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antibiotic use, or vitamin use. However, three potential intervening variables were identified:
compliance (number of pills missed), contraceptive use, and extra visits. One participant in
the zinc group was found to have 9 infections and 7 extra visits, and therefore considered to
be a potential outlier. A statistical analysis done without that subject did not change the
results.

Table 2
Characteristics of Study Participants (N = 261
Placebo Group
n = 11
31.6 years.

Age

Zinc Group
n = 15
29.7 years.

Daily dietary zinc intake

6.1 mg.

5.68 mg.

Pills missed during study

18.2,

8.3,

Vaginal infections in 6 months
prior to study

2.9,

2.9,

Extra visits for vaginal complaints

3

15

Persistent infections

1

3

Courses of antibiotics during study

4

7

Vitamin and/or calcium users

4

6

Oral contraceptive or depo-provera users

4

8

Expressed as a mean.
In order to determine if the three potential intervening variables were statistically
significantly different between groups, a 2 sample t-test analysis was performed on each
variable. None were found to be statistically significant. Table 3 shows the statistical data
of these three variables.
If a woman was found to have a persistent vaginal infection during the study, a
urogenital culture was obtained. This occurred three times in the zinc group. One culture
was positive for E. coli and she was treated with a seven day course of cephaloxin; the other
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two confirmed a heavy growth of gardnerella and Candida albicans. A persistent vaginitis
was found once in the placebo group; that subject had one urogenital culture confirming
Candida albicans in a mixed infection, and another culture confirming gardnerella in a
diagnosis of BV.

Table 3
Potential Intervening Variables
Mean
Compliance
Placebo
Zinc
Contraceptive Use
Placebo

SD

18.2

15.6

8.3

13.1

0.364

0.505

0.667

0.488

Extra Visits
Placebo

0.273

0.647

Zinc

1.00

1.85

Zinc

t

df

P

1.71

19

0.10

1.53

21

0.14

1.41

18

0.18

Hypothesis Testing
A summary of the incidence of vaginal infections prior to and during the study can
be found in Table 4. In order to compare the incidence of vaginitis after the treatment (zinc
or placebo) effect, the number of prior vaginal infections was combined with the initial visit
data. Since no treatment had been administered at the initial visit, if participants were
diagnosed with a vaginal infection at that time, that infection was included with the prior
infections.
Statistical Analysis
In order to test for differences in the incidence of vaginal infections between the
placebo group and the zinc group at post-treatment, a t-test analysis for independent means
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was performed. Table 5 shows this information. There was no significant difference found
(p = 0.16). The research hypothesis that women between the ages of 18 - 45 prone to
vaginal infections who take 30 mg of zinc gluconate daily would have fewer cases of
vaginitis than women who do not take a supplement during a six month time frame was
rejected.

Table 4
Summary of Incidence of Vaginal Infections in Participants (N = 26)
Yeast
Study

Mixed
Prior
Study

Group
Zinc (n=15)

BV
Study
Prior

1 Infection
2-3 Infections
< 3 Infections
Total Infections

2
8
2
31

4
3
1
14

1
3
2
19

3
1
0
5

3
2
0
7

1
2
0
6

6
13
4
57

8
7
1
25

Placebo (n=l 1)

Prior

Study

Prior

Study

Prior

Study

Prior

Study

1 Infection
2-3 Infections
< 3 Infections
Total Infections

1
7
1
23

1
1
0
3

2
2
I
10

1
2
0
5

1
0
1
5

1
0
0
1

4
9
3
38

3
3
0
9

Prior

Total
Prior
Study

Table 5
Statistical Analysis of Placebo Group and Zinc Group (N = 26)
Vaginitis
Episodes
Placebo
(n=ll)

Total

Range

Mean

SD

9

(0-3)

0.82

1.06

Zinc
(n=15)

25

( 0-7)

df

t-value

22

1.45

1.88

1.67

On further examination of data from the zinc group, it appeared there was a
difference in the mean incidence of yeast, dropping from 19 prior to the study (m = 1.26) to
5 following zinc supplementation (m = 0.33). A paired one sample t-test analysis
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confirmed a significant decrease in the incidence of W C in women taking 30 mg of zinc
gluconate daily (t = 2.23, p = 0.021).
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CHAPTERS
DISCUSSION AND IMPLICATIONS

Discussion
Results
The research hypothesis for this study was that women between the ages of 18 - 45
prone to vaginal infections who take 30 mg of zinc gluconate daily would have fewer cases
of vaginitis than women who did not take a supplement during a six month time frame. It
was found that the overall occurrence of vaginitis between the placebo group and the zinc
group at post-treatment was not significantly different (p = 0.16). Thus the hypothesis was
rejected. However, a significant decrease in the incidence of W C infections was noted in
the zinc group (p = 0.021 ).
Per a 24 hour dietary recall, the 26 women participating in the study had a mean
daily zinc intake of 5.86 mg, while the RDA for zinc is 12 mg per day. This group of
women with documented recurrent vaginal infections can be classified as having inadequate
zinc intake based on the 24-hour diet recall. It is interesting to note that the participant with
the most documented vaginal infections ( 14 prior to and during study) had the lowest zinc
intake (0.13 mg/day). This subject was undernourished based on her 24-hour diet recall.
She reported consuming only one small meal that day and on typical days.
Neuman’s Model
Even though the research hypothesis was rejected, some data from the study seem to
support the theory that zinc has impact on the vaginal ecosystem. Women in this study had
inadequate zinc intakes and had recurrent vaginal infections. Women treated with zinc had a
decrease in the incidence of W C . Recalling the vaginitis theory based on Neuman’s
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Model (see Rgure 2), the internal lines of resistance represent the vaginal ecosystem. Part
of this ecosystem is T cells, which are responsible for attacking foreign organisms. Walsh,
et al., ( 1994) stated that “Even a mild or marginal zinc deficiency in humans is characterized
by decreased natural killer cell activity and alterations in T cell subpopulations”. Therefore,
the lines of resistance may be weakened by inadequate zinc intake.
The flexible line of defense acts as a buffer to prevent invasion of stressors, in this
case vaginitis, and can be affected by nutrition. A woman with good overall nutrition is
likely to have stronger defenses against illness than a woman with inadequate or poor
nutrition. Using zinc supplementation may help strengthen the flexible line of defense.
There may be other factors not yet identified that can strengthen a woman's defenses against
recurrent vaginal infections.
Inferences from Literature Review
The researcher found no significant difference in the overall vaginal infection rate
between the placebo group and the zinc group at post-test. There was however a decrease in
the rate of yeast infections in the zinc group from 19 to 5. One could theorize that the
lactobacilli in the vagina have more impact on yeast infections than BV. In fact, Edman et al.
(1986) found that zinc deficiency reduced the immunity of mice to Candida albicans, while
a zinc excess was a protective factor.
There have been no studies done using zinc as a prevention for vaginitis. However,
if the review of literature is re-examined, several consistencies can be found. Scheer (1998)
stated that a zinc deficiency could lead to impaired immune function. Edman et al. ( 1986)
found that zinc deficiency depresses a number of cellular immune functions, including T
cell proliferation. Walsh et al. (1994) state that depression of B and T cell formation is
manifested as a progressive increase in opportunistic infections, especially Candida
albicans. Nyirjesy (1997) states that women with recurrent W C have been found to have
reduced antigen specific T-lymphocyte reactivity. All of this literature supports the theory
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that zinc deficiency reduces the T cell population in the vaginal ecosystem, thereby placing a
woman at risk for infection with Candida albicans.
There are three documented cases of zinc being used as a treatment for recurrent or
resistant trichomonas. Andrews et al. ( 1994) used bacitracin plus zinc, Houang et al. {1997)
used zinc sulfate douches plus metronidiazole, and Willmott et al. ( 1983) used oral zinc
sulfate. All three of these cases were successful at eradicating the trichomonas with the
addition of zinc when conventional therapies had failed.
There have been prior studies on using zinc as a topical treatment for resistant
vaginal infections and there have been prior studies on zinc deficiency and recurrent
vaginitis. However, this is an original study on supplementing zinc in women prone to
recurrent vaginal infections, so the researcher had no other study with which to compare
these results.
Threats to Internal Validity
The procedure was assured validity through the use of the double-blind technique.
Neither the researcher nor the study participant knew if the subject were taking a zinc
supplement, or a placebo. Asking the participant to bring in her capsule bottle at the
appropriate times to determine if she took them correctly protected internal validity. If a
variability existed in the daily consumption of capsules, close record of this was kept in the
researcher’s notebook and the participant was counseled.
Threats to internal validity of the study were of most concern in the area of attrition.
It was assumed that most women who had problems with recurrent vaginitis would be
motivated to find solutions to their problems and this motivation would help with retention
and follow through. Women are often frustrated that the health care system has little to
offer for prevention of recurrent vaginal infections and therefore may have been willing to
try alternative methods of treatment or prevention. Most of the women contacted initially
agreed to participate in the study, yet the attrition rate was high.
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It was hoped that the sample size of at least 30 participants in both the zinc and
placebo groups would provide a margin for attrition with enough remaining numbers to
perform meaningful statistical analyses. However, with the small sample size and the high
attrition rate, that did not happen. Randomizing whether the participant received the zinc or
placebo helped assure validity. Selection criteria facilitated similar subjects, and
randomization of groups again minimized these threats. Subjects were selected based on no
other risk factors being present.
The attrition rate for the study was 37%, or 15 of 41. Because participants were not
required to inform the researcher nor asked why they decided not to participate, specific
reasons cannot be quoted in all cases. Three of the participants became pregnant. Several
who dropped cited reasons such as not remembering to take their capsules, being unable to
follow the guidelines for taking capsules, or not having enough time to schedule the
required visits. One participant was dropped because it was discovered that she was 17
years old and below the age of informed consent.
The Hawthorne effect was minimized because both groups of women being studied
received an intervention. They both took pills, and both groups came in at three month
intervals to be examined.
History effects on the participants were minimized because they were not asked to
change any of their current dietary or behavioral habits, and were not encouraged to make
lifestyle changes such as changes in sexual practices. Becoming pregnant was a maturation
threat that could not be controlled. If a participant became pregnant during the study, she
was withdrawn. The researcher stayed in contact with the study participants throughout the
six months. The researcher or research assistant collected all pertinent data to describe what
happened during the course of the study (see Appendix B). Participants were offered free
office calls for symptoms of vaginitis while they were enrolled in the study.
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T .im itafinns

This Study was limited by several factors. Small sample size was a major limitation
(N=26). This factor placed severe limits on performing meaningful statistical analysis.
Absence of a plasma or urinary zinc level measurement in the subjects to document zinc
deficiency was a concern. This factor was cost-prohibitive in this study environment.
Providing zinc supplementation at only one dosage also limited the range of this study as
different effects may be noted at different dosages.
The study of nutrient deficiencies is a complex phenonemon. Use of the 24 hour
diet recall gives the researcher only a small sample of a subject's true dietary intake. There
are multiple relationships between nutrients that can affect absorption and utilization. The
only such factor this study attempted to control was the relationship between calcium and
zinc. Factors that were not controlled for because of the small sample size were the use of
herbs, contraceptives, vitamins, antacids, and sexual practices.
An assumption made in this study was that participants were heterosexual and
monogamous. No control could be made for participant's sexual partners changing sexual
partners. Another assumption was that by supplementing zinc at 30 mg (which is over the
RDA of 12 mg), subjects would be adequately nourished. An inadequate zinc intake may
represent only one nutrient deficiency in a subject's diet. How other nutrient deficiencies
may affect vaginitis has not been researched. A larger study would enable a researcher to be
more selective or controlling in regards to some of these factors.
During the data collection process, the researcher did ask about recent intercourse
before the physical exam as semen can alter pH readings. However, the participants were
not questioned about recent use of douches, or sexual practices. Douching can alter pH
readings. Oral/genital sex can increase the occurrence of BV. The participants were
discouraged from using douches as part of the general hygiene information given to patients
with recurrent vaginitis. However, objective measures for vaginitis may have been affected
by the lack of documentation in regards to douching and sexual practices.
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Suggestions for Further Research
A future study with a larger sample size would be of great benefit to nursing
research. Based on the researcher’s experience with this study, several modifications can be
suggested. The next researcher may want to limit the study to women with just recurrent
W C as this study showed a decrease in W C in women supplementing zinc. Or she may
want to expand to include greater numbers of subjects with recurrent or resistant
trichomoniasis as prior research has shown zinc to be effective at eradicating this infection.
Having several study groups, taking different dosages of zinc such as 15 mg, 30 mg, 45 mg,
75 mg up to 100 mg, would also provide needed information. This study could also
incorporate serum zinc measurements to supply additional data related to zinc deficiency. It
is possible that the effects of zinc supplementation are not evident in a six month time
frame. A study for a one year period of time may provide different results.
It is also possible that starting with a population prone to vaginal infections skewed
the results. A study encompassing a random sample of all women might decrease the
incidence in general and provide better insights into the effects of zinc supplementation.
A recent study shows a possible link between cigarette smoking and BV (Brunk,
1999). Therefore, further research should include data collection on the incidence of
tobacco use. Using a topical zinc treatment for recurrent vaginitis, such as a suppository or
cream, may also be worth investigating.
Implications
Application to Practice
It is estimated that one-half of adult women in the US consume less than 7.5 mg of
dietary zinc daily (Wood & Zheng, 1997). The US RDA for zinc in adult women is 12 mg.
The study participants consumed an average of 5.86 mg daily, and were known to suffer
from recurrent vaginal infections. Since a decrease in the incidence of W C was noted, and
no long-term detriments to zinc supplementation are documented, women might benefît
from daily zinc supplement to prevent recurrent W C . The noted zinc deficiency alone in
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the subjects, known to be prone to recurrent vaginal infections, suggests the need to increase
zinc either by improved nutritional intake or by supplementation.
Summarv
Although this study did not show a statistically significant difference in the
incidence of overall vaginitis in women taking a zinc supplement versus a placebo, it is still
intriguing to note that women prone to vaginal infections were found to have inadequate zinc
intake based on a 24 hour diet recall, taking in on average less than half the RDA of zinc. It
is also noteworthy that women supplementing zinc did experience a decrease in the
incidence of recurrent W C . Clinically, if one encounters a woman with recurrent vaginal
infections, it may be prudent to administer a 24-hour diet recall to investigate the possibility
of a zinc deficiency.
Vaginitis is a condition of multiple and interrelated causation. One potentially
contributing factor is inadequate zinc intake. While this factor was not statistically
supported in this study, this researcher recommends a larger, more complex and
longitudinal study.
A main function of the nursing profession is to assist the client to recognize
relationships among the physiological, psychological, sociocultural, developmental, and
spiritual components of life. In regards to recurrent vaginitis, the advanced practice nurse
needs to go beyond examination of the woman's vaginal symptoms, and explore with the
client her lifestyle practices. Hygiene, sexual practices, smoking, and poor dietary habits
may all be contributing factors to recurrent vaginal infections.
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APPENDICES

Appendix A
Subject’s Consent Form
I understand that this is a study of recurrent vaginal infections. It is estimated that one-half of
women in the United States may not get enough zinc in their diet. Zinc deficiency is associated with the
body’s immune system not working well. The knowledge gained through this study is expected to help
nurses and physicians provide helpful information to women in preventing recurrent vaginal infections.
I also understand that:
1.) Participation in this research study is voluntary.
2.) Participation in this research study will involve me taking either a zinc supplement (30 mg o f zinc) as
a capsule, or a placebo capsule (a gelatin capsule filled with com starch) on a daily basis.
3.) Calcium and iron can decrease the amount o f zinc absorbed by your body. Therefore, your zinc
supplement o r placebo should be taken two hours before or after any dairy products, calcium supplements,
antacids, iron supplements, or multi-vitamins containing calcium or iron. Attached is a list o f low calcium
and low iron foods which you may take the zinc supplement with.
4.) 1 have been selected to participate in this study because 1 have had at least two clinician diagnosed
vaginal infections in a six month time period, or one infection that has not gotten better.
5.) There are no known physical or emotional risks involved with taking zinc supplements.
6. ) 1 will need to be examined by the researcher three times in the six month study. Once to receive
instructions and the supplement, once at three months into the study, and again at six months. These visits
will be free o f charge.
7.) There will be no cost, other than transportation to and from the office, involved in my participation.
8.) The information 1 provide, and the results o f my vaginal exam will be kept strictly confidential. Data
will be coded so that identification o f individual participants will not be possible.
9.) A summary o f the study results will be made available to me upon request. Please initial here if you
would like to receive a copy o f the study results____________________.
10.) If I develop symptoms o f a vaginal infection, I am free to visit the researcher, or another clinician, to
seek treatment. These visits for vaginal symptoms will be free o f charge during the six month study. The
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researcher will need to have any such infection recorded for her study, so I will need to provide that
information to her if care was sought through another health care provider, or if I used over the counter
remedies.
11.) I will also need to report to the researcher if I take any oral antibiotics during the course of the study.
1 acknowledge that;
1.) I have been given the chance to ask questions regarding this research study, and these questions have
been answered to my satisfaction.
2.) In giving this consent, I understand that my participation is voluntary and 1 may stop at any time using
the postcard with my patient identification number provided by Bonnie Bartz without it affecting the care 1
receive from her. the physicians, or staff at Alpena OB/GYN.
3.) 1 give permission to the researcher to release information obtained in this study to scientific literature.
I understand that 1 will not be identihed by name.
4.) Phone numbers o f the researcher and the chairperson at Grand Valley State University (GVSU) Human
Research Review Committee are listed below. I understand 1 may contact them for questions about the
research. R esearcher Bonnie Bartz (517)356-0504. Chairperson: Dr. Phyllis Gendler (616) 895-3516.
For questions about your rights in the study please contact Paul Huizenga at (616) 895-6611.
5.) I acknowledge that I have read and understand the above information, and that I agree to participate in
this study.

Participant's Signature

Witness

Date

Date
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Appendix B
Researcher’s Notebook
Pt. m.#_
Name
Address
Phone #
DOB_

Age
AB

Race__
Occupation _____
Medical Problems
Food Allergies___
Contraceptive Use_
Current medications, herbs, vitamins, OTC products.

Documentation of previous episodes of vaginitis
Date

Date

Svmptoms

Svmptoms

pH

pH

KOH whiff

KOH whiff

Wet Mount

Wet Mount

Phvsical exam

Phvsical exam

Treatment

Treatment

Taken as directed?

Taken as directed?
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Pt. ID.#

Date

Date

Svmptoms

Symptoms

pH

pH

KOH whiff

KOH whiff

Wet Mount

Wet Mount

Phvsical exam

Phvsical exam

Treatment

Treatment

Taken as directed?

Taken as directed?

Study Consent Form Signed________

.(Date)

Instructions Reviewed with Participant.

.(Initials)

Capsule

A

or

B
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Exam Data
Initial Exam ______________________(Date)
Symptoms______________________________
pH _______________
Wet Mount

KOH Whiff Test

___________________________

Physical Exam
Treatment

__

Taken as directed?
Intercourse or contraceptive use within 24 hours prior to exam?

Three Month Exam _____________________ (Date)
Symptoms____________________________________
pH _______________
Wet Mount

KOH Whiff Test

___________________________

Physical Exam
Treatment
Taken as directed?
Intercourse or contraceptive use within 24 hours prior to exam?

Final Six Month Exam

(Date)

Svmptoms
pH

KOH Whiff Test

Wet Mount
Phvsical Exam
Treatment
Taken as directed?
Intercourse or contraceptive use within 24 hours prior to exam?
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Pt. ID. #

Pt. ID.#_
Significant Events During Study
Episodes of vaginal symptoms
(Date)
Svmptoms
dH

KOH Whiff Test

Wet Mount
Physical Exam
Treatment
Taken as directed?

.(Date)
Symptoms.

pH

---------

KOH Whiff Test

Wet Mount
Physical Exam
Treatment
Taken as directed?

.(Date)
Symptoms.
pH _____

KOH Whiff Test

Wet Mount
Physical Exam
Treatment
Taken as directed?.

47

Pt. ID.#_
Medications Taken
Date

Date

Diagnosis

Diagnosis

Prescription

Prescription

Length of treatment

Length of treatment

Date

Date

Diagnosis

Diagnosis

Prescription

Prescription

Length of treatment

Length of treatment

Major Diet Changes
Date ______________
Description

Change in Sex Partner
Date ________________
Date ________________

Major Change in Life Stressors
Date ________________________

Incident.

Date ________________________

Incident.

Date _______________________

Incident
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Appendix C
Patient Instructions
Dear Potential Study Participant,
Thank you for considering being involved in this study. As a sufferer of recurrent
vaginal infections, you know first hand the pain and frustration that comes with this illness.
One of the most frustrating things for me, as a nurse, is not being able to tell you how to
prevent these infections from happening. With this study, I hope to be able to show that
zinc supplementation can help break this aggravating cycle. In order for the study to be
successful, it is essential that you follow these simple guidelines below. If you have
questions or concerns at any time, please feel free to call me or Kendra Robinette at the
office (356-0504 or 734-2586).
This study involves two groups of participants. One group will receive a placebo (a
capsule with just a filler inside). The other group will receive an actual zinc supplement.
There will be three times in the next six months I need to see you. Your first appointment
will be to receive your capsules, sign the consent form, answer your questions, and get a
vaginal exam done. The second appointment will be at three months into the study. At that
appointment, you will need to bring in your capsule bottle. Kendra will be counting your
remaining capsules to assure that you are taking them on a regular basis. Please don’t
forget your bottle. You will receive your second vaginal exam at that time. The third and
final visit will be at the completion of the study, in six months. This appointment will be a
repeat of the three month appointment. The vaginal exams are being done to determine if
your vagina is in a healthy state, or if there is any yeast or bacteria present. I hope to see
that over time, the group taking zinc will show an improvement in the overall health of their
vaginas.
You will not know if you are taking zinc or the placebo until the end of the study.
Neither will I. Kendra is keeping track of that information. That is why your bottles are
only marked A or B. It is important in research to keep that data confidential for several
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reasons. One is if you knew you were taking a placebo, you would be less inclined to take
it on a daily basis. The other is if the researcher knew who was in the zinc group and who
was in the placebo group, I might start looking for improvements in the zinc group, and thus
skew the data I get from your vaginal exams.
Calcium and iron can make your body absorb less zinc. For that reason. I’m asking
you to take your capsule at least two hours before or after you eat any foods, or take any
vitamins containing calcium or iron. I suggest that if you take a multivitamin, you take it in
the morning. Then, take your zinc or placebo capsule at bedtime either with just a glass of
water, or with a food that does not contain calcium or iron. Many antacids contain calcium,
so please avoid any antacids for two hours before or after your capsule. Below is a list of
low calcium and iron foods you may take your capsule with.
Foods that can be taken with your capsule
Graham crackers

Toast

Soda crackers

Vegetables

Tea (without milk or creamer)

Jell-0

Cookies

Cake

Fruit pie (without ice cream or raisins)

Juice (not calcium enriched)

Prunes

Fruit

If at any time during the study you develop symptoms of a vaginal infection, please
call and make an appointment with me. I will see you free of charge for this appointment.
If you do have a vaginal infection, you will be given the normal treatment. I will not be able
to supply the prescription free of charge. If you have an infection that is not responding to
treatment, I may find it necessary to perform a lab culture. I will not be able to supply the
lab work free of charge. If you develop a infection on the weekend, or for some other
reason, cannot make it in to see me, you may use an over-the-counter treatment, or see
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another health care provider, but be sure you report to me any treatments you use during the
study.
You have been supplied a postage paid postcard. If for any reason, you wish to no
longer participate in the study, simply drop the postcard in the mail. It has only your patient
identification number on it. You will not be reprimanded, nor in any way treated differently
by me or any of the staff at Alpena OB/GYN. No explanation is necessary.
I know this is a big commitment of time and energy on your part. I want to assure
you that all information is confidential, data will be recorded with your patient identification
number only, not your name. After the data has been processed, the individual records will
be destroyed. I want to thank you for your participation. It is my hope that from this small
study, a much larger study can be done that could eventually bring hope and relief to
thousands of fellow vaginal infection sufferers.

With thanks and appreciation.

Bonnie R. Bartz
Women’s Health Nurse Practitioner
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Appendix D
Data Collected for Placebo Group

Subject
9222Initial visit
3 mos.
visit
6 mos.
visit
Subject
2550initial visit
3 mos.
visit
6 mos.
visit
Subject
5783Initial visit

4.3

3 mos.
visit
6 mos.
visit

4.5

Subject
4269Initial visit
3 mos.
visit

4.2
4..0

6 mos.
visit
Subject
5495Initial visit
3 mos.
visit
6 mos.
visit

4.3

+2 yeast

5.3
4.5
4.5

occ. clue
cell
+2 clue
cells

Scant d/c,
mild
irritation

NA

Diflucan

-

NA

NA

-

NA

NA

NA

Flagyl

+

Scant d/c

4.0

-

•

NA

NA

4.5

•

-

NA

NA

5.5

+3 clue
cells

green d/c
with odor

NA

d o odor

NA

Flagyl for
7 days
then
Flagyl 500
m gx 1
with
intercourse
IC

d o odor
and green
d/c

NA

Phone
interview

+1 clue
cells

NA

NA

+2 WBCs,
neg. clue
cells

NA

NA

NA

NA

NA

NA

NA

NA

NA

IC

+

-

NA

+

-

4.8
4.5
4.3

1 yeast, +1
WBCs
+3 clue
cells

-
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5.0

few RBCs

5.0

-

4.8

Few
WBCs

Subject
3248Initiai visit
3 mos.
visit

4.8

+2 clues

4.5

+ 1 yeast

6 mos.
visit
Subject
8441 Initial visit
3 mos.
visit
6 mos.
visit
5/99
6/99

4.2

+ 1 yeast

4.0

+1 yeast

Subject
10642Initial visit
3 mos.
visit
6 mos.
visit

4.5

-

-

mucousy
/creamy
d/c
-

NA

NA

NA

NA

copious
mucousy
d/c
scant
milky d/c

NA

NA

NA

Cleocin
vag. cream

white d/c
NA
and itching

Diflucan
150 mg X
3, then
Diflucan
100 mg
every week
X8 weeks
NA
Terazol7
vag. cream

-

mild
NA
itching
Red vulva, NA
scant white
d/c
NA

-

spotting

NA

4.5

RBCs

Self-tx’d
Self-tx’d

yeast
yeast

Subject
3206Initial visit
3 mos.
visit

4.3

+4
lactobacilli

not
recorded

+2 yeast

6 mos.
visit

4.3

+1 yeast

Subject
10217 Initial visit
3 mos.
visit

4.5

+1 clue
cells

+

5.5

+4 clue
cells

+

6 mos.
visit

5.3

+4 clue
cells

+

7/13/99

5.5

+4 clue

+

NA

Diflucan
Diflucan

After abx.
NA

NA

NA

Diflucan

NA

Diflucan

NA

Flagyl

NA

Metro-gel

Irritation,
milky d/c,
odor

Candida
albicans

Burning,

Heavy

Flagyl bid
for 7 days,
weekly X
4, and
Diflucan
Flagyl for

Scant d/c
with
itching
Slight itch
with scant
d/c
Red vulva
with slight
irritation
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NA

cells

visit

Subject
10800Initial visit
3 mos.
visit

4.5

+4 clues

tearing,
odor, ex.
red, thick
yellow d/c
Slight
greenish
yellow d/c
Yellow d/c
with
burning

+

4.5

Gardnerella

subject
and her
partner

NA

Cleocin
vag. cream

NA

NA

6 mos.
visit
Note. The dosages of vaginitis treatments used were standardized as specified on page 57,
unless otherwise specified. Abbreviations: d/c = discharge, mod. = moderate, NA = Not
Applicable, WBCs = White Blood Cells, RBCs = Red Blood Cells, IC = Insufficient
criteria to provide prescription for treatment.
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Appendix E
Data Collected for Zinc Group

Subject
5756
Initial Visit
3 mos.
visit
6 mos.
visit
3/26/99
5/29/99
Subject
7873
Initial visit
3 mos.
visit
6 mos.
visit
Subject
5846
Initial visit
3 mos.
visit
6 mos.
visit
5/14/99
visit

4.5
4.0
4.3
Self-tx’d
Self-tx’d
5.2
4.8
4.8

6 mos.

+2 clue
cells
yeast
yeast
+ 1 clue
cells
+ 1 clue
cells
+1 clue
cells

NA

NA

-

Scant d/c

NA

IC

NA

Mycelex 7
Mycelex 7
Flagyl

+

Red vulva

-

Mod.
NA
milky d/c
Dry vagina NA

-

RBCs

4.8

WBCs

-

4.8

+4 clue
cells

+

4.8
5.5

+
+ 1 clue
cells

+

+2 clue
cells
+1 clue
cells
+1 clue
cells

+

4.8

+1 clue
cells

4.5

+1 clue

IC

-

5.0

5.0

NA
-

4.5

6/7/99 visit Telephone
call
5.0
Subject
7854
Initial visit
3 mos.
visit
6 mos.
visit
Subject
8990
Initial visit
3 mos.
visit

+1 clue
cells

+
+

-
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IC
IC

NA

NA

Spotting,
slight
burning
Small d/c

NA

NA

NA

NA

+4 yellow
d/c,
burning
Same
symptoms
Slight d/c
with odor

NA

Flagyl

NA

Slight d/c
with odor
Slight d/c
with odor
Burning,
odor

NA

Cleocin
vag. cream
Flagyl X7
days, then
1 Hagyl
po with
intercourse
Metro-gel

NA

Flagyl

NA

Flagyl

Burning,
itching

NA

Metro-gel

-

Shows

Cleocin

NA

cells

visit

heavy
vag. cream
gardnerella (on Flagyl
for d/c in
stool).
NA (Note: Cleocin
pt. cannot vag. cream
and a
tolerate
series of 3
Flagyl)
Diflucan
NA
Metro-gel

Subject
2316
Initial visit

5.0

+4 yeast,
+2 clue
ceils

+

Yellow d/c,
red vulva

3 mos.
visit
6 mos.
visit

4.9

+2 clue
cells
+4 clue
cells

+

Burning

+

4/20/99
visit

5.0

+4 clue
cells, +1
yeast

+

Burning,
d/c,
irritation,
red vulva
Burning,
d/c with
odor

5/26/99
visit

5.0

+3 clue
cells

+

Burning,
itching, d/c

NA

Subject
5022
Initial visit

5.0

+4 clue
cells

++

Burning,
d/c with
odor

3 mos.
visit

4.5

+2 clue
cells

6 mos.
visit
Subject
5916
Initial visit
3 mos.
visit

NA

Not done on menses
+1 clue
cells

Copious
d/c with
minor
irritation
No
complaints
Milky d/c
with
burning

4.5

5.3

+

4.5

Candida
albicans

Metro-gel
and
Diflucan

Candida
albicans

NA

Cleocin
vag. cream
and
Diflucan
Cleocin
and
Diflucan
Metro-gel

NA

Metro-gel

NA

NA

NA

Flagyl

NA

NA

+

Slight itch
and odor
SUght
odor and
irritation

Prophylact
ic Hagyl
and
Diflucan at
end of
menses
Metro-gel

NA

Hagyl

+

Red vulva.

Shows e.

Cleocin

6 mos.
visit
4/12/99
visit

4.8

+1 clues

+

5.2

+1 clues

4/26/99

5.3

+ l clue
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cells, +1
yeast

visit

5/25/99
visit

5.0

+2 yeast,
+1 clue
cells

7/26/99
visit

4.3

+4 yeast

8/3/99 visit 5.0
8/12/99
visit
8/30/99

4.5

Subject
1419
Initial visit
3 mos.
visit
6 mos.
visit

5.0

Subject 42
Initial visit

5.0

3 mos.
visit
6 mos.
visit
3/25/99
visit
Subject
11131
Initial visit
3 mos.
visit
6 mos.
visit
Subject
5195
Initial visit
3 mos.
visit

4.8

6 mos.

5.0

5.3
5.3

+1 clue
ceils
+1 clue
cells
+4 clue
cells
+4 clue
cells
+1 clue
cells, +1
yeast
+ 1 clue
cells,+1
yeast

4.8

RBCs

Telephone
call
4.5

NA

+

+

+

scant d/c,
odor and
irritation

coli

Chunky
milky d/c
with odor,
red vulva

NA

Itching
and d/c

NA

Burning

NA

Diflucan x
3, then
weekly
Diflucan x
12 weeks
Flagyl

Itchy d/c

NA

IC

Burning

NA

Cleocin
vag. cream
Pt.
declined
treatment
Cleocin
vag. cream
Flagyl

+

NA
Mod.
yellow d/c
Scant
creamy d/c

+

NA

+4 clue
cells

NA
NA

vag. cream
and
Diflucan,
then
Keflex
Flagyl and
Diflucan

Slight d/c
with itch

NA

Diflucan
and Flagyl

Mucousy
yellow d/c
Spotting

NA

NA

NA

NA

Itching

NA

Diflucan

+4 d/c

NA

Flagyl

4.0

-

White d/c

NA

NA

4.3

-

Spotting

NA

NA

4.8

+3 clue
cells

Normal

NA

IC

5.3

+3 clue
cells

NA

Flagyl

4.0

WBCs

Thick
white d/c,
itching
Creamy

NA

NA

-

57

visit
7/25/99
visit
Subject
3238
Initial visit
3 mos.
visit
6 mos.
visit
Subject
3256
Initial visit
3 mos.
visit
6 mos.
visit
Subject
10054
Initial visit
3 mos.
visit
6 mos.
visit

Telephone
call
5.5

NA

4.5

Mod.
lactobacilli

Not
completed
5.0
5.0
4.8
4.6

d/c
Itching,
white d/c
Milky d/c
at introitus

NA
+

-

Diflucan

NA

Flagyl

NA

NA

NA

IC

Spotting

NA

NA

Mod.
yellow/
green d/c
Thick
white d/c

NA

NA

NA

NA

Normal

NA

NA

Normal

NA

NA

-

+2 clue
cells
+ 1 clue
cells
WBCs

-

+ 1 clue
cells

4.5
Telephone
call

NA

NA

NA

unless otherwise specified. Abbreviations: d/c = discharge, mod. = moderate, NA = Not
Applicable, WBCs = White Blood Cells, RBCs = Red Blood Cells, IC = Insufficient
criteria to provide prescription for treatment.
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Appendix F
Vaginitis Treatment Protocol
The protocol within the practice where the researcher is employed states the
appropriate medication for treating a yeast infection is considered to be one of the
following: fluconazole (Diflucan) 150 mg single oral dose; terconazole (Terazol) 80 mg
vaginal suppository, one suppository nightly for three nights; terconazole vaginal cream
(Terazol 7), one applicator vaginally nightly for seven nights; miconazole (Monistat) 2%
cream, 5 grams vaginally for 7 nights, tioconazole (Vagistat) 6.5% cream, 5 gram single
dose. Any of these treatments are deemed adequate according to research done by Sobel,
Faro, Force, Foxman, Ledger, Nyiijesy, Reed and Summers ( 1998), and Roe and Gudi,
(1997).
Appropriate treatment for a bacterial vaginal infection includes; metronidazole
(Flagyl) 500 mg orally twice a day for 7 days. Alternative treatments include clindamycin
2% vaginal cream (Cleocin), 1 applicator vaginally nightly for 7 nights; clindamycin 300 mg
orally twice a day for 7 days (used only with resistant infections); metronidazole vaginal
cream (Metro-gel), one applicator vaginally every night for 5 nights (Roe & Gudi, 1997).
If a woman returned after treatment of vaginitis with complaints of a vaginal
infection within 6 months of the initial complaint, she again underwent physical exam, wet
mount, KOH whiff test, urogenital culture, and pH. It was also determined that she had
taken all medications as prescribed initially. This differentiates between recurrent infection
as opposed to inadequate treatment. The urogenital culture helps determine if there are
organisms present other than yeast or gardnerella such as E. coli.
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Appendix G
Summary of Infections Prior to and During Study - Placebo Group (N=l I)

9222
2550
5783
4269
5495
10642
3248
8441
3206
10217
10800
Totals for
Placebo
Group

H
5BV
2 Yeast
2BV
2BV
3BV
4 Mixed
1BV,2
Yeast
3 Yeast
2BV
2BV, 1
Yeast
IBV, 1
Mixed
38 Total:
23 BV,
10 Yeast,
5 Mixed

Yeast
BV
BV
BV

Yeast

BV
-

-

0
0
1 BV
0
0
0
1 Yeast

Yeast
BV

Yeast
BV

Yeast
Mixed

2 Yeast
BV

2 Yeast
2 Yeast
2BV, 1
Mixed
0

BV

-

Included in
Prior
Infections
(pretreatment)

9 Total:
3BV,
5 yeast,
1 mixed

Summary of Infections Prior to and During Study - Zinc Group (N=15)

5756
7873

5022

2 Yeast
IBV, 1
Yeast
3BV
IBV, 1
Mixed
2BV
4BV,4
Yeast
4BV

5916

3 Yeast

BV

5846
7854
8990
2316

-

-

-

BV

2 yeast
-

-

-

-

2BV

BV

BV

BV

-

BV
Mixed

BV
BV

BV
Mixed

BV

BV
BV
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2 Yeast
0
2BV
2BV

-

2BV
3 Mixed, 1
BV
IBV

3BV.2
Mixed, 1
Yeast

4BV .2
Mixed, 1
Yeast

-

2 Mixed

1419

2BV

BV

42
11131
5195

6 Yeast
2BV
3 Yeast

Mixed
BV

3238
3256

2BV
IBV, 1
Mixed, 1 K.
pneumonia
2BV,2
Mixed
57 total:
31 BV,
19 Yeast,
6 mixed,
1 other

10054
Totals for
Zinc Group

-

BV

Mixed

-

-

1 Yeast

-

-

-

BV

-

1 Yeast

-

-

-

-

-

-

Included in
Prior
Infections
(pretreatment)

IBV, 1
Mixed
1 Yeast
0
1 Yeast, 1
BV
0
0
0
26 Total:
14 BV,
6 Yeast,
6 Mixed
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